Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Tandem Diabetes Care (NASDAQ:TNDM) and raises the price target from $55 to $58.
August 05, 2024 | 11:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Matt Miksic maintains an Overweight rating on Tandem Diabetes Care and raises the price target from $55 to $58.
The Overweight rating and increased price target from a reputable analyst at Barclays is likely to positively influence investor sentiment and drive short-term price appreciation for Tandem Diabetes Care.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100